Pablo Cagnoni, M.D., has led the development, approval, and/or commercialization of more than twenty approved medicines. He is currently President and Head of Research and Development at Incyte. Previously, Dr. Cagnoni served as CEO of Laronde and Executive Partner at Flagship Pioneering. Prior to this, he held leadership roles at Rubius Therapeutics, Tizona Therapeutics, and Onyx Pharmaceuticals. Dr. Cagnoni has also led clinical development in past roles, including Global Head of Clinical Development at Novartis Oncology, CMO at Allos Therapeutics and CMO at OSI Pharmaceuticals. Dr. Cagnoni received his Doctor of Medicine (M.D.) from the University of Buenos Aires School of Medicine and completed fellowships in Hematology and Oncology at the Mount Sinai Medical Center in New York, and in Stem Cell Transplantation at the University of Colorado Health Sciences Center.